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• A number of recent studies have allayed fears about 
antidepressants precipitating suicidal behaviour in young 
people. Indeed, antidepressants appear to be conspicuous 
by their absence of use in young people who die by suicide.
• Furthermore, there is concern that the reduced prescribing of 
antidepressants to young people may be associated with an 
increase in youth suicide in the United States.
• Although not first-line treatment, antidepressants should not 
be denied young people if psychosocial and cognitive 
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behavioural therapies are not effective for major depression.he
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1 “Evaluating medicines: let’s use all the
idence” was a timely reminder of the potential limitations
relying solely on randomised clinical trials (RCTs) in
making decisions about the use of medications.
Nowhere is this more applicable than in the contentious area of
antidepressants, particularly the selective serotonin reuptake
inhibitors (SSRIs), and potential suicide risk in children and
adolescents.2 There have been sporadic case reports of an associa-







placebo to people who may be suicidal, but, even more so, is the
impossibility of mounting a sufficiently powered study because of
the low base rate of suicide. For example, it has been calculated
that, if one were to use the RCTs of antidepressants which have
been published, then it would have been necessary to have
recruited about 1.9 million subjects to detect a 20% decrease in
suicide.7 It is also pertinent that, in the RCTs which have led to
concerns, suicidal behaviours had not been the specific focus of
research, but were spontaneously reported events,8 and it could be
argued that an overdose of active medication would be more likely
to evoke reporting than an overdose of placebo.
Because of limitations in the interpretation of RCTs, it has been
observed that real-life clinical monitoring may be the only way in
which clinicians and drug regulators can make reasoned decisions
about some treatments. Indeed, with regard to antidepressants and
suicide in young people, there have been a number of recent
naturalistic observations published, and it is important to
incorporate them into clinical decision making.
Ludwig and Marcotte analysed SSRI use and suicide data from
27 countries, and found a strong association between an increase
in antidepressant prescribing and a reduction of suicide in people
older than 15 years,9 although the data were not conclusive for
people aged 10–15 years. However, there have been studies from
four countries which can inform us further about suicide and
antidepressants in the young.
Jick et al analysed data from the United Kingdom General
Practice Research Database (GPRD), which contains more than 35
million patient-years of information. They found a similar risk of
suicide when commencing one of either two tricyclic antidepres-
sants or two SSRI antidepressants, and a decreasing risk with
time.10 An accompanying editorial noted that the analysis simply
demonstrated that antidepressants were being “prescribed for the
right indication, and that they do not immediately eliminate
suicide risk. That we knew”.11 It is important to note that Jick et al
extended their analysis to examine adolescent suicide,10 and found
no suicides in those aged 10–19 years who were on one or other of
the study drugs. However, they reported that there were 15 people
in that age group in the GPRD who had died by suicide, and none
had received an antidepressant drug. One might, perhaps provoc-
atively, ask why the media did not criticise practitioners for not
using antidepressants in those people.
That the data analysed by Jick et al were not simply an artefact of
British practice has been demonstrated by subsequent reports from
three other countries. In Sweden, Isacsson et al reported a
toxicological study of more than 14 000 suicides between 1992
and 2000 and compared them with control subjects.12 They found
that SSRIs were under-represented compared with other antide-
pressants in people who died by suicide (odds ratio, 0.83; 99% CI,
0.77–0.90). They also addressed the issue of suicide in younger
people, and found in the 15–19 years age group that SSRIs had a
lower relative risk (RR, 0.14; 95% CI, 0.05–0.43) for suicide
compared with non-SSRI antidepressants. In people younger than
15 years, there were 52 suicides and no SSRIs were found by
toxicological screening, although other antidepressants were
detected in seven of these people. A study from the United States
provided even more striking results — Moskos et al reported that,
in a series of 49 suicides aged 13–21 years, “not one demonstrated
therapeutic or subtherapeutic levels of psychotropic medications
upon autopsy”.13 More recently, Søndergård et al, in a pharmaco-
epidemiological study of youth suicide in Denmark between 1995
and 1999, found that none of 42 suicides aged 10–17 years had
been treated with SSRIs in the 2 weeks before their deaths, and
none of the 37 boys who died by suicide had ever been treated
with antidepressants at any time during the study period.14
However, there is one other US study in which one of 36 suicides
under the age of 18 years had both sertraline and bupropion
detected by toxicological analysis, and the authors noted that “the
detection of antidepressants at autopsy was quite rare”.15
With other research indicating that two-thirds of young suicides
had significant mood disorders,16 it would not have been unex-
pected for more young people in these five studies to have recently
been prescribed antidepressants before their suicide. Indeed, for
only one out of 194 young suicides to have had evidence of
antidepressant use is quite remarkable, and totally incongruent
with the assertion that SSRI antidepressants may precipitate
suicide in the young.
No antidepressant has yet been approved for use in major
depression in children and adolescents in Australia, and fluoxetine 10 • 19 November 2007
VIEWPOINTis the only antidepressant so approved in the UK and the US.
However, it is of interest to reflect that the SSRIs fluvoxamine and
sertraline are approved for use in obsessive compulsive disorder
(OCD) in children and adolescents in Australia, and there have not
been reports of suicide with the use of those antidepressants in
young people with OCD — yet another piece of collateral evidence
(again, not from an RCT) which lends confidence to the use of
SSRI antidepressants in young people.
This viewpoint should not be interpreted as promoting uncriti-
cally the use of antidepressants in young people. Antidepressants
are not necessarily first-line treatment, and they should be used
only as an adjunct to psychosocial and cognitive behavioural
therapies, and after consultation with the patient and family.
However, these recent studies add considerable weight to the
previous cautious endorsement by Rey and Dudley of the appro-
priate use of antidepressants in young people.17
In view of this recent research, it is not unexpected that concern
has been expressed in the US that, in 2004, for the first time in a
decade, the previously declining suicide rate in young people
increased.18,19 This coincided with a reduction in antidepressant
prescribing, which was almost certainly brought about by initial
fears that have since been allayed by these recent studies. Indeed,
it is not unexpected that Bridge et al recently concluded that the
“Benefits of antidepressants appear to be much greater than risks
from suicidal ideation/suicide attempt across indications”.2
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